Erythromycin is an old and well-established antimicrobial agent which has assumed greater therapeutic importance because of its activity against increasingly prevalent pathogens such as Legionella, Campylobacter, and Chlamydia spp. (1, 13, 59, 79) . It is generally perceived within the infectious disease community as a safe and effective antibiotic. These circumstances have prompted research groups throughout the world to continue exploration for novel modifications of erythromycin which would improve upon the therapeutic properties of the parent compound. During the past few years, several new derivatives of erythromycin have been identified during preclinical evaluation as sufficiently promising to warrant clinical investigations.
Although erythromycin is the only member of the large class of macrolide antibiotics to have achieved significant clinical utility in the United States, several macrolides other than erythromycin have been developed and used in other countries (58) . These macrolides differ from erythromycin in the size and/or substitution pattern of the lactone ring system; in recent years, new derivatives of these other macrolides have also been prepared and evaluated for clinical utility. Pertinent properties and clinical results for all of these new macrolide derivatives are summarized in this minireview.
CHEMISTRY OF MACROLIDES Degradation of erythromycin. Erythromycin is well-known to decompose under acidic conditions to first yield its 8,9-anhydro-6,9-hemiketal and subsequently its 6,9; 9,12-spiroketal ( Fig. 1) (49) . Neither of these decomposition products possesses any significant antimicrobial activity, although the anhydrohemiketal has been suggested as the principal agent responsible for many of the gastrointestinal side effects of erythromycin therapy (63) .
Passage of erythromycin through the stomach can result in substantial acid-catalyzed degradation (and loss of antibiotic activity). Considerable success in protecting erythromycin from decomposition in the stomach has been achieved by using highly water insoluble salts (e.g., lauryl sulfate or stearate) or acid-stable enteric coatings. A new example of the former approach is erythromycin acistrate (2'-O-acetylerythromycin stearate); a thorough review of this product has just appeared (26) .
In a different approach, two new salts of propionylerythromycin (N-acetylcysteinate and mercaptosuccinate) which combine antibiotic and mucolytic activities in a single agent have been prepared (21, 27) . In all of these cases involving different esters, salts, and formulations of erythromycin, the active antibiotic ingredient is always erythromycin base (75), * Corresponding author. and these agents are not covered in the present review. Instead, this review focuses only upon those new agents whose antibiotic activities are the result of a derivative of erythromycin rather than erythromycin itself.
New derivatives of 14-membered macrolides (erythromycin A). A number of research groups in recent years have synthesized new derivatives of erythromycin A which retain potent antimicrobial activity while offering improved pharmacokinetic properties. All of these new entities can be regarded as ways to inhibit the relatively facile decomposition illustrated in Fig. 1 . This objective has been accomplished by modification of the functional groups which participate in the degradation reaction, namely, the ketone at C-9, the hydroxyl group at C-6, the proton at C-8, and the diol moiety at C-11 and C-12 (Fig. 2) .
The ketone at C-9 has been modified in several ways. The earliest of these modifications was roxithromycin, selected as the candidate with the best therapeutic index from a new series of oxime derivatives synthesized at Roussel-Uclaf (J. F. Chantot Erythromycylamine is an older derivative of erythromycin, formally the result of reductive amination of the C-9 ketone; however, both it and its N-benzylidene derivative gave extremely low levels in blood when administered orally to humans (53) . Dirithromycin, a new oxazine formed from erythromycylamine and (2-methoxyethoxy)acetaldehyde, was selected by Boehringer-Ingelheim on the basis of high levels in tissues (52) . Formerly designated AS-E 136, it is being developed jointly with Eli Lilly & Co. (formerly LY237216).
A third modification of the ketone of erythromycin utilized a Beckmann rearrangement of its 9-oxime derivative, followed by reduction and N-methylation (12, 28 Prevention of intramolecular cyclization other than by modification of the ketone has also proven fruitful. Alkylation of the hydroxyl group at C-6, which is involved in the initial cyclization step, has been thoroughly investigated, resulting in the synthesis of 6-0-methylerythromycin by Taisho Pharmaceutical Co. (56 Roxithromycin. Comprehensive reviews of roxithromycin, in which its in vitro activity against a wide variety of pathogens was approximately equivalent to that of erythromycin, have been published (14, 60, 64) . In other publications, roxithromycin was approximately half as potent as erythromycin against most susceptible staphylococci and streptococci (6, 19, 46) . Against other respiratory pathogens, roxithromycin was equivalent to erythromycin against species of Legionella (6, 45) but two-to fourfold less active than erythromycin against Haemophilus influenzae and Branhamella catarrhalis (4, 47) . Activity against the genital pathogens Chlamydia trachomatis (11), Neisseria gonorrhoeae (6, 46) , and Haemophilus ducreyi (72) was approximately equivalent to that of erythromycin; against species of Campylobacter, it was two-to fourfold lower than that of erythromycin (8, 22) . Against other aerobic and anaerobic bacteria, roxithromycin was less active than erythromycin (38) . These studies generally concluded that roxithromycin had no distinct advantage over erythromycin in vitro but that favorable differences in pharmacokinetic properties might afford clinical advantages over erythromycin.
Dirithromycin. Only one major study of the antimicrobial activity of dirithromycin has been published (41) . Dirithromycin was two-to fourfold less active than erythromycin in vitro against gram-positive bacteria (U. Lechner, K. R. Appel, R. Maier, and E. Woitun, 8th Int. Symp. Future Trends Chemother., p. 31, 1988) . Although less active than erythromycin against a variety of clinical isolates, dirithromycin was fourfold more active against Bordetella pertussis (K. R. Appel, U. Lechner, H. Meier-Ewert, and G. Ruckdeschel, 28th ICAAC, abstr. no. 921, 1988). Against both Campylobacterjejuni and C. coli, activity was equal to that of erythromycin (30) . As with roxithromycin, the potential advantage of dirithromycin is in its pharmacokinetic properties rather than its in vitro activity.
Azithromycin. Although approximately two-to fourfold less active than erythromycin against most staphylococci and streptococci (29, 65) , azithromycin was more potent against other organisms, including a number of gram-negative bacteria which are considered to be resistant to erythromycin (12, 65) . Regarding other pathogens of the respiratory tract and auditory canal, azithromycin was 2-to 8-fold more active against H. influenzae, Haemophilus parainfluenzae, B. catarrhalis, and Legionella pneumophila (4, 29, 65 ) and more than 10-fold more active against Pasteurella multocida (65) and Mycoplasma pneumoniae and M. hominis (67) . It was more potent against N. gonorrhoeae (65) and Ureaplasma urealyticum (67) while comparable to erythromycin against C. trachomatis (78) . Activity against Campylobacter species and a variety of anaerobic bacteria varied from slightly higher to slightly lower than that of erythromycin (22, 65) . Based on its in vitro spectrum, azithromycin may expand the range of therapeutic utility traditionally assigned to macrolides.
Clarithromycin. Clarithromycin exhibited the same spectrum of in vitro activity as erythromycin (32) . It ranged from equally potent to fourfold more potent than erythromycin against susceptible staphylococci and streptococci (20, 31, 35) . Activity of clarithromycin was increased two-to fourfold against Legionella species (35, 45) , B. catarrhalis (20) , and P. multocida (31) ; in contrast, activity against H. influenzae and H. parainfluenzae was approximately half that of erythromycin (7, 9, 34, 51) . Clarithromycin was more than 10-fold more active against C. trachomatis (11, 73) while comparable to erythromycin against N. gonorrhoeae (11, 31) and H. ducreyi (24) . Activity was equivalent to that of erythromycin against various species of Campylobacter (8, 9) . In vitro activity was increased against Bacteroides fragilis, Clostridium species, and some other anaerobic bacteria (20, 31, 32) . Clarithromycin appears to have significantly increased potency against organisms traditionally considered to be susceptible to macrolides.
Flurithromycin. Although few publications have reported the antibacterial activity of flurithromycin, it appears to be very similar to erythromycin in vitro (41) ; activity against staphylococci, streptococci, H. influenzae, and B. catarrhalis was approximately the same as that of erythromycin (37, 61, 76) . One study reported some improvement in activity against anaerobic bacteria (37) .
Rokitamycin. A large volume of data on rokitamycin has been published in Japanese journals, but much less has appeared in English. Rokitamycin has an antimicrobial spectrum similar to those of erythromycin and josamycin, a related 16-membered macrolide (41, 57, 77) . Rokitamycin is especially potent against L. pneumophila and M. pneumoniae, two important respiratory tract pathogens (39, 54) . Like other 16-membered macrolides, it is active against bacteria which are inducibly resistant to erythromycin but inactive against strains which are constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics (41) .
Miokamycin. A significant amount of information about miokamycin has been published in Japanese and Italian journals. Miokamycin was generally less potent in vitro than rokitamycin (41, 77) . It was less active than erythromycin VOL. 33, 1989 against many aerobic bacteria but was more active against Legionella species and several anaerobic bacteria (41, 50, 81) . Its activity was comparable to that of erythromycin against Chlamydia and Ureaplasma spp. but superior to that of erythromycin against M. hominis (66). It also inhibited strains of Staphylococcus aureus which were inducibly resistant to erythromycin (48) .
Emerging pathogens. The earlier resurgence of macrolide antibiotics was largely the result of the clinical efficacy of erythromycin against pathogens such as Legionella spp. As other microorganisms now emerge as clinical problems, particularly in immunocompromised patients, it is encouraging that new macrolide derivatives have shown some activity against such pathogens. Further developments may lead to a therapeutic role for macrolides against some of these increasingly problematic pathogens.
Macrolides are not generally used as antituberculous agents. However, synergistic effects have recently been reported for roxithromycin with either rifampin (15) or tumor necrosis factor and amikacin (10) against Mycobacterium avium; the activity of azithromycin against M. avium was also enhanced by tumor necrosis factor (10) . In other studies, flurithromycin showed an additive effect with some other antibiotics against Mycobacterium species (37) and clarithromycin inhibited the growth of M. leprae in a mouse footpad infection model of leprosy (36) .
Another problem organism is Toxoplasma gondii, against which the macrolide spiramycin has been used (23) . Recent studies have shown that roxithromycin, clarithromycin, and azithromycin all inhibited intracellular growth of T. gondii (17) and were effective at high doses against murine acute toxoplasmosis (3, 16, 18); the last compound was also effective at high doses against murine toxoplasmic encephalitis, suggesting its accumulation in the cerebrospinal fluid of the mice (3). Synergism with interferon enhanced the in vivo efficacy of roxithromycin (43) .
Finally, azithromycin was more effective than erythromycin against infections in hamsters caused by Borrelia burgdorferi, the causative agent of Lyme disease (R. C. Johnson, C. Kodner, and M. Russell, 27th ICAAC, abstr. no. 235, 1987 
